TsingKe / 擎科生物
Beijing gene-synthesis + CRISPR tools platform (oligo/gene synth, sgRNA)
About TsingKe / 擎科生物
Beijing gene-synthesis and CRISPR tools platform TsingKe (擎科生物 / 北京擎科生物科技) provides oligo and gene synthesis, Sanger and NGS services, life-science reagents and instruments, and sgRNA / HDR gene-editing synthesis for academia and biopharma from Beijing Economic-Technological Development Area. Founded 2017, the company runs an integrated synthetic-biology gene factory spanning genomics products, research equipment and biomanufacturing CRO/CDMO with roughly 1,250 to 1,400 staff at IPO prospectus scale. Mid-size China gene-editing / CRISPR tools leftover beyond RiboBio FIX and Ubigene soft-skip.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2017
- Headquarters
- China
- Employees
- 9
- Open positions
- None listed
- Dealroom signal
- 33.6/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Client focus
- B2B
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| IPOOther financing | Jan 2026 | $0 | — | Undisclosed | ↗ |
| SERIES BOther financing | Dec 2022 | $55M | $220M | Jinyu Maowu Investment · Capitallink | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for TsingKe / 擎科生物 is 1.1K monthly website visits, up 189.5% over the last three months. TsingKe / 擎科生物's team declined 10% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
TsingKe / 擎科生物 in its local ecosystem
The TsingKe / 擎科生物 office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A5 investors entered at this stage
- SIShengyu Investment
SB China Capital- YCYueyin Venture Capital
- JIJinyu Maowu Investment
- CACapitallink
Other known investors1 additional known investor
Cowin Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about TsingKe / 擎科生物 on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See TsingKe / 擎科生物’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








